Do DIO1 polymorphisms reduce T4 to T3 conversion and lower free T3?

Type 1 deiodinase (DIO1) is a critical selenoprotein responsible for converting thyroxine (T4) into the biologically active triiodothyronine (T3) in peripheral tissues. Genetic variations within the DIO1 gene can significantly alter this enzymatic process, leading to distinct systemic thyroid hormone profiles.

Mechanistic explanations

• Enzymatic downregulation: The DIO1 single nucleotide polymorphisms (SNPs) rs2235544 and rs11206244 directly modulate deiodinase catalytic activity. Specifically, the rs2235544 A allele and the rs11206244 T allele are strongly associated with reduced DIO1 expression and activity.
• Hormonal phenotype: This impairment in enzymatic efficiency decreases the peripheral conversion of T4 to T3, resulting in a characteristic biochemical phenotype of lower free T3 (FT3) and a reduced FT3/FT4 ratio, while free T4 (FT4) remains preserved or elevated. Conversely, the rs2235544 C allele increases conversion efficiency, resulting in lower reverse T3 (rT3) and a higher FT3/FT4 ratio.

Clinical implications

• Hormone replacement requirements: Because these genetic variations directly dictate how efficiently T4 is metabolized, DIO1 polymorphisms (such as rs2235544) predict individual levothyroxine dosage requirements during thyroid hormone replacement therapy.
• Neuropsychiatric associations: The rs11206244 T allele, which correlates with reduced conversion and altered thyroid hormone parameters (including higher FT4), is associated with an increased risk of lifetime major depression in specific subgroups of women.

Bottom line

• Common DIO1 polymorphisms (rs2235544 and rs11206244) impair the peripheral conversion of T4 to T3, causing lower active free T3 levels despite normal or elevated free T4. This genetic profile can influence levothyroxine dosage requirements and is associated with a higher risk of major depression in women.